GHK-Cu is unusual among the peptides in our research library. It is genuinely ancient — in molecular terms — present in human plasma, well-characterized across five decades of peer-reviewed research, and widely used in legitimate cosmetic formulations. What the literature says about it is both more and less than the claims commonly made.

At a glance

What: A naturally occurring three-amino-acid peptide bound to copper, found in human blood plasma and released from damaged tissue proteins during injury.

Research areas: Wound healing · Skin regeneration and photoaging · Collagen and elastin synthesis · Hair follicle biology · Anti-inflammatory gene expression

Evidence: Fifty years of peer-reviewed mechanistic and cell-culture research; solid topical cosmetic dermatology trials; sparse clinical data for injectable use.

Status: A legitimate regulated cosmetic ingredient in the EU, UK, and US (INCI: Copper Tripeptide-1). Not approved as a medicine anywhere. Injectable form sold only as a research chemical.

What is GHK-Cu?

GHK-Cu is a complex consisting of the tripeptide glycyl-L-histidyl-L-lysine (GHK) bound to a single copper(II) ion. The tripeptide itself (GHK) and the copper-bound form (GHK-Cu) are both present naturally in human blood plasma, though in trace quantities. GHK can be released from larger parent proteins — including collagen, SPARC, and several others — during tissue injury, which placed it firmly within the class of biologically relevant "matrikines": small peptide fragments of extracellular matrix proteins (the scaffolding between cells) with signaling activity (Pickart, 2008).

GHK: Gly-His-Lys · GHK-Cu: [Gly-His-Lys]⋅Cu²⁺

One of the most frequently cited observations about GHK is that its plasma concentration declines markedly with age. Pickart's early work reported plasma GHK levels in the range of 200 ng/mL in young adults, dropping to roughly 80 ng/mL in subjects in their sixties (Pickart, 1983). This age-related decline is a recurring theme in the literature's framing of GHK's biological role — though the causal relationship between declining plasma GHK and age-related tissue changes remains an inference rather than a demonstrated mechanism.

Discovery

GHK's discovery is a genuinely interesting story in the history of bioactive peptides. In 1973, Loren Pickart, then a graduate student at the University of California, San Francisco, was investigating why old rat liver cells took on the protein synthesis characteristics of young cells when cultured with human serum from young donors but not from old donors. Through a long process of biochemical fractionation, Pickart identified the active factor as the tripeptide GHK (Pickart & Thaler, 1973). The copper-binding properties of the molecule were characterized shortly after, and the peptide-copper complex became the focus of subsequent research.

Over the following decades, Pickart continued to publish on GHK-Cu, eventually authoring or co-authoring dozens of review articles and primary papers that formed much of the current English-language literature. Independent groups in France (notably François-Xavier Maquart and colleagues at Reims), Poland (Gruchlik and collaborators), and Asia added substantial additional research.

Proposed mechanisms

Copper delivery

At its simplest, GHK-Cu is described in the literature as a biological copper-delivery molecule. Copper is an essential cofactor for several enzymes involved in extracellular matrix remodeling, including lysyl oxidase (critical for collagen cross-linking), superoxide dismutase (antioxidant defense), and cytochrome c oxidase (mitochondrial respiration). GHK binds copper with high affinity and can facilitate its uptake by cells and its delivery to these enzyme systems (Pickart et al., 2015).

In plain English: GHK-Cu's core job is to shuttle copper — an essential trace mineral — into cells where it's needed to build and repair skin and connective tissue.

Collagen and elastin synthesis

A series of studies by Maquart and colleagues characterized the effects of GHK-Cu on extracellular matrix production in fibroblast cultures. Their 1993 paper reported that GHK-Cu stimulated synthesis of collagen, elastin, glycosaminoglycans, and proteoglycans in cultured human dermal fibroblasts, with effects observable at low nanomolar concentrations (Maquart et al., 1993). Subsequent work extended these findings to in vivo rat wound models, where topical GHK-Cu was reported to increase collagen and glycosaminoglycan deposition in granulation tissue (Maquart et al., 1988).

Anti-inflammatory gene expression

One of the more striking published findings concerns GHK's effect on gene expression. In a 2010 paper, Pickart and colleagues reported results from a Broad Institute Connectivity Map analysis in which GHK exposure was associated with altered expression of approximately 4,000 human genes in skin fibroblast cultures — roughly one-third of all genes analyzed. The authors described the pattern as broadly reparative: upregulation of DNA repair pathways, antioxidant systems, and tissue remodeling genes, combined with downregulation of inflammatory pathways (Campbell et al., 2012).

This "4,000 gene" figure appears frequently in popular discussions. It is worth stating what it does and does not mean: it reflects the number of genes whose expression changed by some statistical threshold in a single in vitro (test-tube / cell-culture) screening experiment, not the number of genes that GHK-Cu "acts on" in any specific biological sense.

In plain English: The widely-shared claim that GHK-Cu "affects 4,000 genes" comes from a single gene-expression screen in cultured skin cells. It shows the molecule is broadly reparative in that dish — not that it rewrites your biology.

Antioxidant enzyme activation

Published research has reported that GHK-Cu can activate or upregulate superoxide dismutase (SOD) and other antioxidant defenses, consistent with its role as a copper-delivery molecule for enzymes that require copper as a cofactor (Beretta et al., 2007).

Wound healing signaling

Beyond its matrix-stimulating effects, GHK-Cu has been reported to influence angiogenesis, fibroblast proliferation, and macrophage activity in wound environments. Its role is commonly described in the literature as a "danger signal" released from damaged matrix proteins that alerts surrounding tissue to initiate repair programs (Pickart & Margolina, 2018).

A note on literature context

Much of the GHK-Cu literature is authored or co-authored by Loren Pickart or by researchers who collaborated with him, reflecting the compound's unusual history as a single-investigator research program that spanned decades. Independent replication by disconnected groups is a useful cross-check, and it does exist — particularly from Maquart's group, the Pickart/Campbell gene expression work done at the Broad, and various cosmetic-industry research laboratories. The literature is not uniform in quality, but it is substantial.

Key research areas

Wound healing

The wound healing literature on GHK-Cu spans rodent models, rabbit models, and several published human studies. Early work using topical GHK-Cu formulations in rat full-thickness wound models reported faster closure, increased granulation tissue, and improved histological markers of healing compared to controls (Counts et al., 1992). Human studies have examined the peptide in chronic wounds, including diabetic foot ulcers and venous stasis ulcers, with published reports suggesting improvements in closure rates (Mulder et al., 1994).

Skin regeneration and anti-aging

GHK-Cu's most commercially consequential research is in dermatology and cosmetic science. Multiple published studies have reported improvements in skin thickness, fine line appearance, and elasticity with topical GHK-Cu formulations. Leyden and colleagues published a 12-week controlled study on facial photodamage, reporting improvements in several clinical parameters with a GHK-Cu-containing cream compared to vehicle (Leyden et al., 2002). Additional work has examined the effect of GHK-Cu on skin barrier function, hydration, and collagen density in peer-reviewed dermatology journals (Finkley et al., 2005).

Hair growth research

A distinct literature has examined GHK-Cu in hair follicle biology. Uno and Kurata published work reporting that copper peptide analogs of GHK stimulated hair follicle growth in mouse models and in follicle organ culture, with effects on enlargement and elongation of anagen-phase follicles (Uno & Kurata, 1993). Additional work characterized GHK's effects on dermal papilla cells, which regulate hair growth cycles (Trüeb, 2018).

Anti-inflammatory research

Beyond the gene expression work, direct measurements of inflammatory mediator output have been reported in several studies. Published findings describe reduced TNF-α and IL-6 production in cell cultures exposed to GHK or GHK-Cu under inflammatory stimulation, and reduced inflammatory cell infiltration in some in vivo injury models (Gruchlik et al., 2012).

Pulmonary and other emerging areas

A more recent and smaller body of research has examined GHK in pulmonary fibrosis models, COPD signatures, and even certain aspects of cancer-related gene signature reversal — the latter primarily on the basis of gene expression database mining rather than in vivo evidence (Zhang et al., 2012). These are exploratory research areas with preliminary findings, not established clinical applications.

Regulatory status

Unlike most peptides discussed in our research library, GHK-Cu occupies a clear and legitimate place in a regulated product category: cosmetic ingredients. In the European Union, it is listed in the Cosmetic Ingredient Database (CosIng) under the INCI name Copper Tripeptide-1 and is compliant with the EU Cosmetics Regulation (EC) No 1223/2009 for topical cosmetic use (European Commission CosIng). In the United States, it is widely used in cosmetic products under the same INCI name and is regulated as a cosmetic rather than a drug ingredient.

This regulatory legitimacy applies specifically to topical cosmetic use. GHK-Cu in any injectable form, or for any therapeutic indication (as distinct from a cosmetic claim), is not approved as a medicine by the European Medicines Agency, the MHRA, the FDA, or any comparable regulator. The injectable research chemical form is in an entirely different regulatory category from the cosmetic ingredient.

Clinical evidence in dermatology

The topical cosmetic/dermatology literature on GHK-Cu is the most developed clinical evidence base for the compound. Published randomized controlled studies have examined facial photoaging, periocular wrinkles, and skin firmness using various GHK-Cu-containing formulations. Effect sizes reported in these studies are generally modest — consistent with what is typical for cosmetic actives — and are best interpreted within the cosmetic rather than therapeutic framework (Abdulghani et al., 1998).

The evidence for topical cosmetic benefit is stronger than for most peptides of this class. The evidence for systemic or injectable use is substantially weaker.

In plain English: The strongest clinical evidence for GHK-Cu is as a topical skincare ingredient in creams and serums — where it's a regulated cosmetic. The injectable research-chemical form is a different story with far less human data.

Forms: injectable versus topical

GHK-Cu exists in two quite different product contexts that should not be conflated:

The published research relevant to each form is partly overlapping (the molecular biology is the same) and partly distinct (the pharmacokinetics, bioavailability, and safety considerations differ entirely).

Current state of evidence

What the research does not show

Framing

This article is a summary of published research. Where dosing or application is discussed, the context is always literature-derived. GHK-Cu is a legitimate cosmetic ingredient under EU regulation, but it is not an approved medicine in any major jurisdiction. The research chemical form is sold strictly for laboratory and in-vitro research. At no point should this article be read as instruction for human use.